|
Loading...
| ||||||||||||||
Recent Publications by AstraZeneca: |  | |
| Genetically Abnormal Circulating Cells in Lung Cancer Patients: An Antigen-Independent Fluorescence In situ Hybridization-Based Case-Control Study.
PURPOSE: We performed a study to determine if a fluorescence in situ... | Authors' Affiliations: Departments of Pathology, Epidemiology, Thoracic | Clin Cancer Res. 2010 Jul 22.
DOI Direct Link |
| The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug compounds.
The liver is the major organ metabolising drugs. The hepatocyte contains a... | Clinical Pharmacology and DMPK, AstraZeneca R&D, Molndal, Sweden. | Methods Mol Biol. 2010;640:375-87.
DOI Direct Link |
| 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
A class of inhibitors of mitogen activated protein kinase-activated kinase... | Department of Biological Sciences, AstraZeneca R&D Lund, S-22187 Lund, | Bioorg Med Chem Lett. 2010 Jun 25.
DOI Direct Link |
| Toxicological and Pathophysiological Roles of Reactive Oxygen and Nitrogen Species.
'Oxidative and Nitrative Stress in Toxicology and Disease' was the subject... | AstraZeneca R&D Safety Assessment, Alderley Park, UK. | Toxicology. 2010 Jul 16.
DOI Direct Link |
| Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * The antiplatelet agent... | AstraZeneca LP, Wilmington, DE 19850-5437, USA. | Br J Clin Pharmacol. 2010 Jul;70(1):65-77.
DOI Direct Link |
AstraZeneca Patents: |  |
| US Patent No. | Title |
| 7674801 | Alkyl urea substituted pyridines |
| 7700604 | Hydantoin derivatives as metalloproteinase inhibitors |
| 7700640 | Process for making phenoxy benzamide compounds |
| 7700782 | Compounds 569 |
| 7705145 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6-(3-morpholinopropoxy) quinazoline |